智能生物解决方案公司启动补充临床研究,为FDA 510(K)提交做准备,支持进军价值数十亿美元的美国市场计划

美股速递
Jan 28

智能生物解决方案公司(INTELLIGENT BIO SOLUTIONS INC)已正式启动额外的临床研究,旨在为其向美国食品药品监督管理局(FDA)提交的510(K)申请提供关键数据支持。这一战略举措旨在加速公司进入价值高达数十亿美元的美国市场,标志着其在全球医疗设备领域扩张的重要一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10